Copyright Reports & Markets. All rights reserved.

Global and Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Insights, Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type
    • 1.4.2 Preface
    • 1.4.3 Eluxadoline
    • 1.4.4 Alosetron
    • 1.4.5 Rifaximin
    • 1.4.6 Loperamide
    • 1.4.7 Diphenoxylate + Atropine
    • 1.4.8 Dicyclomine and Hyoscyamine
  • 1.5 Market by Application
    • 1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Application
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size, Estimates and Forecasts
    • 2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2015-2026
    • 2.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2015-2026
  • 2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Market Size by Region (2015-2020)
    • 2.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
  • 2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Region (2021-2026)
    • 2.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2021-2026)
    • 2.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2021-2026)

3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitor Landscape by Players

  • 3.1 Global Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers
    • 3.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (2015-2020)
    • 3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers by Revenue
    • 3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2015-2020)
    • 3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue in 2019
    • 3.2.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Manufacturers
  • 3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution, Product Types
    • 3.4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type
    • 3.4.3 Date of International Manufacturers Enter into Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type (2015-2020)
    • 4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020)
    • 4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2015-2020)
    • 4.1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2021-2026)
    • 4.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application (2015-2020)
    • 5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020)
    • 5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2015-2020)
    • 5.1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2015-2020)
  • 5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Application (2021-2026)

6 Japan by Players, Type and Application

  • 6.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2015-2026
    • 6.1.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY Growth 2015-2026
    • 6.1.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue YoY Growth 2015-2026
    • 6.1.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share in Global Market 2015-2026
  • 6.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Players (International and Local Players)
    • 6.2.1 Japan Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players by Sales (2015-2020)
    • 6.2.2 Japan Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players by Revenue (2015-2020)
  • 6.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Review by Type (2015-2020)
    • 6.3.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
    • 6.3.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2015-2020)
    • 6.3.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2015-2020)
  • 6.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Forecasts by Type (2021-2026)
    • 6.4.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2021-2026)
    • 6.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2021-2026)
    • 6.4.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Type (2021-2026)
  • 6.5 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Review by Application (2015-2020)
    • 6.5.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
    • 6.5.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2015-2020)
    • 6.5.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2015-2020)
  • 6.6 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Forecasts by Application (2021-2026)
    • 6.6.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Application (2021-2026)
    • 6.6.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Application (2021-2026)
    • 6.6.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Application (2021-2026)

7 North America

  • 7.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2015-2026
  • 7.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
    • 7.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020)
    • 7.2.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020)
    • 7.2.3 U.S.
    • 7.2.4 Canada

8 Europe

  • 8.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2015-2026
  • 8.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
    • 8.2.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
    • 8.2.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
    • 8.2.3 Germany
    • 8.2.4 France
    • 8.2.5 U.K.
    • 8.2.6 Italy
    • 8.2.7 Russia

9 Asia Pacific

  • 9.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2015-2026
  • 9.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
    • 9.2.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2015-2020)
    • 9.2.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
    • 9.2.3 China
    • 9.2.4 Japan
    • 9.2.5 South Korea
    • 9.2.6 India
    • 9.2.7 Australia
    • 9.2.8 Taiwan
    • 9.2.9 Indonesia
    • 9.2.10 Thailand
    • 9.2.11 Malaysia
    • 9.2.12 Philippines
    • 9.2.13 Vietnam

10 Latin America

  • 10.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2015-2026
  • 10.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
    • 10.2.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
    • 10.2.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
    • 10.2.3 Mexico
    • 10.2.4 Brazil
    • 10.2.5 Argentina

11 Middle East and Africa

  • 11.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2015-2026
  • 11.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
    • 11.2.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
    • 11.2.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
    • 11.2.3 Turkey
    • 11.2.4 Saudi Arabia
    • 11.2.5 U.A.E

12 Company Profiles

  • 12.1 Astellas Pharmaceuticals
    • 12.1.1 Astellas Pharmaceuticals Corporation Information
    • 12.1.2 Astellas Pharmaceuticals Description and Business Overview
    • 12.1.3 Astellas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 12.1.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
    • 12.1.5 Astellas Pharmaceuticals Recent Development
  • 12.2 Actavis
    • 12.2.1 Actavis Corporation Information
    • 12.2.2 Actavis Description and Business Overview
    • 12.2.3 Actavis Sales, Revenue and Gross Margin (2015-2020)
    • 12.2.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
    • 12.2.5 Actavis Recent Development
  • 12.3 Pfizer
    • 12.3.1 Pfizer Corporation Information
    • 12.3.2 Pfizer Description and Business Overview
    • 12.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 12.3.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
    • 12.3.5 Pfizer Recent Development
  • 12.4 GlaxoSmithKline
    • 12.4.1 GlaxoSmithKline Corporation Information
    • 12.4.2 GlaxoSmithKline Description and Business Overview
    • 12.4.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
    • 12.4.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
    • 12.4.5 GlaxoSmithKline Recent Development
  • 12.5 Salix Pharmaceuticals Ltd
    • 12.5.1 Salix Pharmaceuticals Ltd Corporation Information
    • 12.5.2 Salix Pharmaceuticals Ltd Description and Business Overview
    • 12.5.3 Salix Pharmaceuticals Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 12.5.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
    • 12.5.5 Salix Pharmaceuticals Ltd Recent Development
  • 12.6 AstraZenenca
    • 12.6.1 AstraZenenca Corporation Information
    • 12.6.2 AstraZenenca Description and Business Overview
    • 12.6.3 AstraZenenca Sales, Revenue and Gross Margin (2015-2020)
    • 12.6.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
    • 12.6.5 AstraZenenca Recent Development
  • 12.11 Astellas Pharmaceuticals
    • 12.11.1 Astellas Pharmaceuticals Corporation Information
    • 12.11.2 Astellas Pharmaceuticals Description and Business Overview
    • 12.11.3 Astellas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 12.11.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
    • 12.11.5 Astellas Pharmaceuticals Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Segment by Type, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
    Preface
    Eluxadoline
    Alosetron
    Rifaximin
    Loperamide
    Diphenoxylate + Atropine
    Dicyclomine and Hyoscyamine

    Segment by Application, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
    Hospitals
    Clinics
    Others

    Regional and Country-level Analysis
    The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

    Competitive Landscape and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Analysis
    Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs business, the date to enter into the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product introduction, recent developments, etc.
    The major vendors covered:
    Astellas Pharmaceuticals
    Actavis
    Pfizer
    GlaxoSmithKline
    Salix Pharmaceuticals Ltd
    AstraZenenca
    ...

    Buy now